FDA Approves Gilead Sciences Drug for 3 Cancers

The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.

Jul 23, 2014 at 1:39PM

WASHINGTON (AP) -- The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences to treat three types of blood cancer.

Regulators approved the drug for patients with forms of chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. The cancers affect an estimated 200,000 patients in the U.S., according to Gilead.

The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.

"In less than a year, we have seen considerable progress in the availability of treatments for chronic lymphocytic leukemia," said FDA's director for cancer drugs, Dr. Richard Pazdur.

The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.

Lymphocytic leukemia first invades bone marrow cells before spreading to the blood and other parts of the body, including the liver and lymph nodes.

The FDA approved Zydelig for leukemia based on a study showing that adding the drug to another cancer therapy, Rituxan, slowed cancer progression. Researchers halted the study early when it became clear the drug was working. FDA said patients taking the Zydelig combination had the potential to live 10.7 months without their disease progressing, compared with about 5.5 months for patients taking Rituxan alone.

The drug will carry a boxed warning, the strongest type, about potentially fatal side effects, including liver toxicity, diarrhea and colon inflammation.

More common side effects with the drug include diarrhea, fever, fatigue, nausea, cough, pneumonia, chills and rash. The drug also frequently lowers white blood cell levels and raises blood sugar.

The Foster City, Calif.-based Gilead Sciences makes an array of antiviral medications used to treat HIV including Atripla, Truvada, and Stribild. The company has also made headlines this year with its breakthrough Hepatitis C drug, Sovaldi, which posted sales of $2.3 billion for the first quarter.

Analysts have estimated Zydelig could eventually reach annual sales between $1 billion and $2 billion per year.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. Click here now.

The Motley Fool recommends Gilead Sciences, GlaxoSmithKline, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers